15 patents
Utility
Treatment of Cancers Using PI3 Kinase Isoform Modulators
16 Nov 23
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.
Howard M. STERN, Jeffery L. Kutok
Filed: 12 Dec 22
Utility
Formulations of (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE
6 Apr 23
Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
Filed: 21 Mar 22
Utility
Heterocyclic Compounds and Uses Thereof
24 Nov 22
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
Filed: 15 Mar 21
Utility
Combination Therapies
4 Aug 22
Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a Flt3 ligand, or a combination thereof.
Jeffery L. KUTOK
Filed: 14 Sep 21
Utility
Solid Forms of Isoquinolinones, and Process of Making, Composition Comprising, and Methods of Using the Same
5 May 22
Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Louis Grenier, Andre Lescarbeau, Praveen Sharma, Daniel G. Genov
Filed: 18 Jan 22
Utility
Combination Therapies
28 Apr 22
Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof.
Jeffery L. KUTOK, Howard M. STERN
Filed: 2 Aug 21
Utility
Methods of Use of Cyclopamine Analogs
9 Sep 21
Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
Filed: 28 Sep 20
Utility
Treatment of Cancers Using PI3 Kinase Isoform Modulators
4 Mar 21
Provided herein are methods, kits, and pharmaceutical compositions that include a P13 kinase inhibitor for treating cancers or hematologic disorders.
Howard M. Stern, Jeffrey L. Kutok
Filed: 14 Apr 20
Utility
Heterocyclic Compounds and Uses Thereof
6 Jan 21
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
Filed: 10 Mar 20
Utility
Processes for Preparing Isoquinolinones and Solid Forms of Isoquinolinones
9 Dec 20
Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
Filed: 2 Jan 20
Utility
Combination Therapies
28 Oct 20
Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a CDK4/6 inhibitor, 2) an HDAC inhibitor, 3) a MEK inhibitor, 4) a mTOR inhibitor, 5) an AKT inhibitor, 6) a proteasome inhibitor, 7) an immunomodulator, 8) a glucocorticosteroid, 9) a BET inhibitor, 10) an epigenetic inhibitor, 11) a PI3K alpha inhibitor, 12) a topoisomerase inhibitor, or 13) an ERK inhibitor.
Jeffery L. Kutok, Howard M. Stern
Filed: 25 Nov 19
Utility
Cyclopamine Analogs
22 Apr 20
Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
Filed: 23 Jul 19
Utility
Methods of Use of Cyclopamine Analogs
22 Jan 20
Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay
Filed: 25 Apr 19
Utility
Heterocyclic Compounds and Uses Thereof
4 Dec 19
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
Filed: 19 May 19
Utility
Heterocyclic Compounds and Uses Thereof
30 Oct 19
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Alfredo C. Castro, Catherine A. Evans, Martin R. Tremblay
Filed: 28 Feb 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first